Edesa Biotech (EDSA) Research & Development (2013 - 2026)
Edesa Biotech (EDSA) posted Research & Development of $1.1 million for Q4 2025, down 8.23% sequentially from $1.2 million in Q3 2025, and up 10.29% YoY from $1.0 million in Q4 2024.
Edesa Biotech (EDSA) Research & Development (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Research & Development for 13 years, with the latest figure at $1.1 million in Q4 2025.
- Quarterly Research & Development rose 10.29% year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (up 18.03% YoY) and the FY2025 annual result came in at $3.7 million, up 27.3% from the prior year.
- Research & Development retreated to $1.1 million in Q4 2025 per EDSA's latest filing, from $1.2 million in the prior quarter.
- Over five years, Research & Development peaked at $8.0 million in Q1 2021 and troughed at $103867.0 in Q3 2024.
- A 5-year average of $2.1 million and a median of $1.2 million in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2021 and 2024: Research & Development jumped 1486.13% in 2021, then slumped 89.11% in 2024.
- Over 5 years, Research & Development stood at $4.0 million in 2021, then tumbled by 65.65% to $1.4 million in 2022, then tumbled by 48.1% to $704458.0 in 2023, then surged by 44.77% to $1.0 million in 2024, then grew by 10.29% to $1.1 million in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $1.1 million, $1.2 million, and $939067.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Edesa Biotech | 43.15 Mn | 43.15 Mn | - | 3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.96 Mn |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.23 Mn |
| Jun 30, 2025 | 939,067.00 |
| Mar 31, 2025 | 484,306.00 |
| Dec 31, 2024 | 1.02 Mn |
| Sep 30, 2024 | 103,867.00 |
| Jun 30, 2024 | 897,305.00 |
| Mar 31, 2024 | 1.18 Mn |
| Dec 31, 2023 | 704,458.00 |
| Sep 30, 2023 | 953,399.00 |
| Jun 30, 2023 | 1.03 Mn |
| Mar 31, 2023 | 1.46 Mn |
| Dec 31, 2022 | 1.36 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 4.55 Mn |
| Mar 31, 2022 | 3.04 Mn |
| Dec 31, 2021 | 3.95 Mn |
| Sep 30, 2021 | 4.13 Mn |
| Jun 30, 2021 | 4.46 Mn |